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ADAPTIVE MULTICENTER DESIGNS FOR CONTINUOUS
RESPONSE CLINICAL TRIALS IN THE PRESENCE OF
AN UNKNOWN SENSITIVE SUBGROUP
DARIA RUKINA
Abstract. The partial effectiveness of drugs is of importance to the
pharmaceutical industry. Randomized controlled trials (RCTs) assum-
ing the existence of a subgroup sensitive to the treatment are already
used. These designs, however, are available only if there is a known
marker for identifying subjects in the subgroup. In this paper we in-
vestigate a model in which the response in the treatment group ZT
has a two-component mixture density (1 − p)N (µC , σ2) + pN (µT , σ2)
representing the treatment responses of placebo responders and drug
responders. The treatment-specific effect is µ = µ
T−µC
σ
and p is the
prevalence of the drug responders in the population. Other patients in
the treatment group react as if they had received a placebo.
We develop one- and two-stage RCT designs that are able to detect a
sensitive subgroup based solely on the responses. We also extend them
to a multicenter RCTs using Hochberg’s step-up procedure. We avoid
extensive simulations and use simple and quick numerical optimization
methods.
1. Introduction
Because of population heterogeneity, treatment effects may vary consid-
erably from one subject to another. In [1] it is reported that on average
only 60% of treated patients react to prescription drugs, whereas the others
either do not benefit or have adverse effects. If a trial showed no significant
average treatment effect, it can be wrong to conclude that the treatment
effect does not exist and that the treatment is futile. There may well be a
subpopulation of subjects for whom the treatment is effective. As an exam-
ple, consider the Clomethiazole Acute Stroke Study [2] where the relative
functional independence of patients with acute hemispheric stroke was in-
vestigated. The trial results showed no significant difference between the
clomethiazole and the placebo groups (56.1% vs. 54.8%) with a p-value of
0.649. However, in the group of patients with TACS (total anterior circula-
tion syndrome), 40.8% reached relative functional independence in contrast
to 29.8% of TACS patients in the placebo group, with a p-value of 0.008.
The idea that there is a proportion of non-responders in the treatment
group is often highlighted in clinical papers [3, 4, 5, 6, 7]. If one has specific
biomarkers which point to the subjects who are likely to respond to an
intervention, then a subgroup analysis is usually conducted in addition to the
standard procedure. Most of the time, however, there is no such information
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about the sensitive subgroup, and a standard designs may fail to prove the
drug’s efficacy.
Moreover, even if the proportion of the sensitive patients is big, there is
another hurdle which can mask a drug-specific effect, namely the placebo.
When its effect is comparable with a drug, the detection of a subgroup is
complicated substantially. This problem may occur in treatments for neu-
rological disorders, where many trials fail to show efficacy, and the reason is
claimed to be a large placebo effect [12, 13, 14]. For our purpose, the placebo
effect is a combination of natural course of the disease, the Hawthorne effect
and other non-specific effects influencing the treatment outcome.
Given the assumptions above, we elaborate a framework in which we are
able to detect the sensitive subgroup based on the following model. Let the
response to the drug, Z, be a normally distributed random variable. We
assume that there are two groups of patients: placebo-only responders with
Z ∼ N (µC , σ2) and placebo-and-drug responders with Z ∼ N (µT , σ2),
where µT > µC . The drug-specific effect, µT − µC , and the placebo effect
are additive. The response in the treatment group is then modelled as a
mixture (see Fig. 1)
ZT ∼ (1− p)N (µC , σ2)+ pN (µT , σ2) ,
where p ≥ 0 is the proportion of placebo-and-drug responders (the sensitive
subpopulation). The design is constructed to determine whether p > 0.
Denote the standardized drug-specific effect as µ = µ
T−µC
σ . Given the stan-
dardized estimates of responses in the treatment group,
Xi =
ZTi − ZC
σ
, i = 1, . . . , n,
the average value X has expectation µp and is distributed as
∑n
k=0
(
n
k
)
pk(1−
p)n−kN ( knµ, 2n). The test based on the average of observations can be used
in deciding between H0 : p = 0 against H1 : p > 0. Along with its simplicity
the mean value statistic can also be used with non-normal responses that
may be encountered in clinical trials.
To control the power of detection, we consider the minimal power over a
region of strong effect, the set of (µ, p) that are deemed to be of interest. We
propose one- and two-stage designs for the single and multicenter trials. This
framework is mainly aimed at the early phase II before the identification of
the drug-responders subgroup.
The outline of the paper is as follows. In Section 2, we introduce the
model, define type I and type II errors, and describe the designs. In Section
3, we discuss the choice of parameters and optimal designs. We present the
planning procedure, from the user (study designer) point of view, with the
plots and tables to guide the choice of parameters. In Section 4, the perfor-
mance of the study designs is illustrated. Section 5 provides an additional
argumentation and discusses further related questions, such as estimation
of µ and p. Section 6 concludes.
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Figure 1. Modelling drug response as a mixture of two
continuous distributions has been proposed to be more rea-
sonable in RCT for some types of indications. On the left,
the control group is centered at zero and the mixture created
in the treatment group is asymmetric with an enlarged upper
tail. If we could separate the responders and non-responders
in the treatment group, we would observe the graphs as in
the right hand side.
2. The designs
In all RCTs discussed in this chapter we consider any treatment group
at any stage to have a corresponding control group of the same size. Let
ZT1 , . . . , Z
T
n and Z
C
1 , . . . , Z
C
n be the responses from the treatment and the
control groups, respectively. For convenience we define normalized responses
as
Y C =
ZC − µC
σ
∼ N (0, 1), Y T = Z
T − µC
σ
∼ (1− p)N (0, 1) + pN (µ, 1),
where µ = µ
T−µC
σ . Since we do not know µ
C and σ, it is not possible to ob-
serve Y T . Instead, we take its estimate, Xi =
ZTi −µˆC
σ , where µˆ
C =
∑n
i=1 Z
C
i
n .
For the design development we assume σ to be known, but in practice we
may use the approximation σˆC =
√∑n
i=1(Z
C
i −µˆC)2
n−1 . In simulations shown
later, we show that the approximation error has a negligible effect on the
results.
In a simple RCT with a single center, the test is based on the mean value
statistic,
X =
X1 + . . .+Xn
n
= Y T − µˆ
C − µC
σ
.
Note that
Y T ∼
n∑
k=0
(
n
k
)
pk(1− p)n−kN
(
k
n
µ,
1
n
)
,
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Figure 2. The region of strong effect, E , is a subset of the
(µ, p) plane satisfying µ ≥ µi if p ∈ [pi, pi+1] where µs <
µs−1 < ... < µ1 and 0 < p1 < p2 < . . . ps+1 = 1.
µˆC−µC
σ ∼ N
(
0, 1n
)
, and the distribution of X is
X ∼
n∑
k=0
(
n
k
)
pk(1− p)n−kN
(
k
n
µ,
2
n
)
.
2.1. Hypothesis testing. The goal of a trial is to determine if there is a
sensitive subpopulation. The decision is based on a statistical test of
(1)
H0 : Y T ∼ N (0, 1) versus
H1 : Y T ∼ (1− p)N (0, 1) + pN (µ, 1), p ∈ (0, 1], µ > 0.
Of course, not all pairs (µ, p) are of equal interest for the drug developer.
It is of small interest if H0 is rejected when H1 is true with some small p
and/or µ. Therefore, it is important to define interesting values of (µ, p),
for which one wants to reject the null.
Definition 1. The region E of strong effect (se) is the set of interesting
pairs (µ, p) such that µ ≥ µi if p ∈ [pi, pi+1], where µs < µs−1 < . . . < µ1
and 0 < p1 < . . . < ps+1 = 1 (see Fig. 2).
In the next two subsections, we introduce the single and the multicenter
RCT designs, for which type I and II errors are defined as follows.
Definition 2. For a simple study, a type I error occurs when a true null is
rejected. A type II error occurs if a false null is not rejected in the presence
of a strong effect. The corresponding type I error rate will be denoted as α
and the maximum of the type II error rate over E is denoted as βse. In the
case of a multicenter study with M centers a type I error occurs if at least
one of the true nulls is rejected, and a type II error occurs if at least m false
nulls among the M1 centers with strong effects are not rejected. Note that
m ≤ M1 ≤ M . The type I error is a family-wise error, while the type II
error depends on M1 and m. The type II error rate maximized over E will be
denoted by βse for the single stage study and βsefw(M1,m) of the multicenter
study.
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2.2. Simple RCT designs - single center RCT. We start with the sim-
plest design: single center, one stage. For the mean value statistic the
hypothesis testing problem is
(2)
H0 : X ∼ N
(
0,
2
n
)
;
H1 : X ∼
n∑
k=0
(
n
k
)
pk(1− p)n−kN
(
k
n
µ,
2
n
)
.
The design of a trial is defined by the sample size n and some positive
threshold η, upon which the decision about a subgroup’s existence is made,
(D1) Reject H0 if X > η.
The chosen test is justified by the following lemma:
Lemma 1. The tests that reject H0 for X > η are uniformly most powerful.
The equivalent formulation of the design is
(D1)
Reject H0 if the p-value
(
X
)
< α, where p-value
(
X
)
= 1− Φ
(
X
√
n
2
)
and α < 0.5.
Here, α is a type I error rate, and η = z1−α
√
2
n , where z1−α = Φ
−1(1 −
α) stands for the standard Gaussian quantile. The probability of a false
negative for a fixed alternative is
(3) β(n, η, µ, p) =
n∑
k=0
(
n
k
)
pk(1− p)n−kΦ
((
η − k
n
µ
)√
n
2
)
.
By Definition 2,
(4) βse(n, α) = max
(µ,p)∈E
β
(
n, z1−α
√
2
n
, µ, p
)
.
As the following lemma shows, one can easily compute βse(n, α) for the
regions E of the form we defined.
Lemma 2. For the region of strong effect defined as in Definition 1, the
maximum type II error rate for the one-stage RCT is
βse(n, α) = max
i=1,...,s
β
(
n, z1−α
√
2
n
, µi, pi
)
.
2.2.1. Two stage designs. By Wald’s theory of sequential analysis, there are
modifications of the RCT design enabling significant reduction in the re-
quired minimum number of the participants. The idea of sequential analysis
is to split the testing process into several steps and update the inference
based on the information accumulated from the previous steps [15]. In the
context of RCT, the steps are the stages of the trial. Having many stages re-
quires additional parameters, which might be difficult to choose. Therefore,
in this paper, we consider only the extension to two-stage designs. We will
show how the introduction of the second stage decreases the total expected
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X1
X2
X2 =
n1+n2
n2
η2 − n1n2X1
η0 η1
Figure 3. Scheme of the trial performed in two stages.
Rejection region is depicted in grey.
number of enrolled patients in comparison with the one-stage design, while
maintaining the same error rates.
For the first stage we propose two stopping rules. First, if the evidence in
favour of the alternative is very strong after the first stage, there is no need
to conduct the second stage. Second, if the evidence in favour of the null is
strong enough at the first stage, one can stop the trial early, claiming the
absence of an effect.
To start with, consider some fixed sample sizes with n1 and n2 participants
at the first and second stages, respectively. We also assume that there
are two different control groups at each stage with the same number of
participants as in the treatment groups. Denote the mean observed values
after the first and the second stages by X1 and X2, and the mean of all
observations as X. The design is described as follows:
(D2)
• If X1 < η0 : H0 is not rejected and the trial is stopped
(strong evidence of an absence of a positive treatment effect);
• If X1 > η1 : reject H0 and stop the trial (strong evidence in favour of H1);
• If η0 ≤ X1 ≤ η1 : conduct the second stage and reject H0 if X > η2
(strong evidence in favour of H1 after two steps).
The rejection region is depicted in Fig. 3 (grey area). For the thresholds,
η0, η1, denote the corresponding probabilities P
(
X1 < η0
)
and P
(
X1 > η1
)
under the null as α0 = Φ
(
η0
√
n1
2
)
and α1 = 1− Φ
(
η1
√
n1
2
)
.
In terms of p-values, this design becomes:
(D2)
Reject H0 if p-value
(
X1, X2
)
< α, where
p-value
(
X1, X2
)
=

1− Φ (X1√n12 ) , X1 /∈ [η0, η1],
η1∫
η0
√
n1
2 ϕ
(
x1
√
n1
2
)(
1− Φ
(√
n2X2+
n1√
n2
(X1−x1)√
2
))
dx1 + α1,
X1 ∈ [η0, η1].
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x1
x2
n1+n2
n2
η2 − n1n2x1
η0 η1 X1
(a) p-value < α1
x1
x2
n1+n2
n2
η2 − n1n2x1
n1+n2
n2
X − n1n2x1
η0 η1X1
X2
(b) p-value ∈ [α1, 1− α0]
x1
x2
n1+n2
n2
η2 − n1n2x1
η0 η1X1
(c) p-value > 1− α0
Figure 4. Computation of the p-value for the trial per-
formed in two stages.
The computation of the p-value is complicated by the fact that the grey
region in Fig.4(b) is not simple. The p-value is an integral of the joint
density function f(X1,X2)(x1, x2) under H0 over the grey area in Fig.4. If
X1 ∈ [η0, η1], we integrate above the line n1+n2n2 X−n1n2x1 = X2+n1n2
(
X1 − x1
)
and for the fixed x1 the probability that x2 is above this line equals 1 −
Φ
(√
n2X2+
n1√
n2
(X1−x1)√
2
)
. Under H0 this p-value is uniformly distributed on
the interval (0, 1), because for any two different realizations of
(
X1, X2
)
,
one of the grey areas (see Fig.4) contains the other one.
The design D is fully determined by the sample sizes in the first and
second stages, n1 and n2, and the probabilities α0 and α1; the overall level
of the procedure is α. These values often satisfy 1 − α0 > α > α1. If this
does not hold, the second stage is not needed. The thresholds η0, η1, η2 can
be computed as
η0 = zα0
√
2
n1
, η1 = z1−α1
√
2
n1
,
η2 such that
∫ η1
η0
√
n1
2
ϕ
(
x1
√
n1
2
)(
1− Φ
((
n1 + n2
n2
η2 − n1
n2
x1
)√
n2
2
))
dx1 + α1 = α.
(5)
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Denote the maximum type II error rate for the two-stage design as βse2 (D,α).
To compute it, we use an expression for the probability of the false negative:
β2(D,α, µ, p) = P
(
p-value
(
X1, X2
) ≥ α|µ, p)
=

β
(
n1, z1−α1
√
2
n1
, µ, p
)
, α /∈ (α1, 1− α0),
β(n1, η0, µ, p) +
∫ η1
η0
βη(n1, x1, µ, p)β
(
n2,
n1+n2
n2
η2(D,α)− n1n2x1, µ, p
)
dx1,
α ∈ (α1, 1− α0).
(6)
We introduce the case α /∈ (α1, 1− α0) in (6), because we will need it later
for the multicenter two-stage design. Similar to the one-stage trial, the
following holds.
Lemma 3. For the region of strong effect defined as in Definition 1, the
maximum type II error rate for the two-stage trial is
βse2 (D,α) = max
i=1,...,s
β2(D,α, µi, pi).
2.3. Multicenter RCT designs. In this section, we generalize the designs
proposed above to multicenter RCTs. We suggest first to conduct single
center RCTs with identical designs in all centers in parallel, with each center
having its own control group. Following this initial stage, the results are
analyzed together in order to make conclusions about the existence of the
subpopulation in each center.
Combining the evidence across multiple centers requires p-values. For
this reason, in the previous subsection, we introduced an equivalent designs
formulation using p-values. We assume patient enrollment in all centres is
done independently, and that all the p-values are independent.
In the single center design one rejects H0 if the p-value is below α, but to
control the family wise type I error rate in the multi-center context at the
level α, we need a multiple testing procedure, such as Hochberg’s step-up
procedure [8]. The whole design is then described as follows:
• Let p-value1,p-value2, . . . ,p-valueM be the set of p-values
at the end of each study (see Eq.D2). Put the p-values in an
ascending order: p-value(1) ≤ p-value(2) ≤ · · · ≤ p-value(M).
• Denote the index of the center corresponding to p-value(k) as c(k).
(D3)
• Given the thresholds, α(1) ≤ α(2) ≤ · · · ≤ α(M), find the index
K corresponding to the largest k such that p-value(k) ≤ α(k).
In Hochberg’s step-up procedure α(k) =
α
M + 1− k .
• The centers c(1) through c(K) are then judged to have sensitive
subpopulations, and the null hypothesis is rejected for them.
There is a complication for a two-stage multicenter design. In the case of a
single center, if the p-value < α1, then H0 is rejected after the first stage.
When more than one center is involved, the condition p-valuei < α1, which
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0
α(1) α(2)
α1
α(3) α(4)
α 1− α0
1c(1) c(2) c(3) c(4) 0
α(1) α(2)
α1
α(3) α(4)
α 1− α0
1c(1) c(2) c(3) c(4)
Figure 5. The figure shows two examples. The green
squares corresponds to the centers for which H0 was rejected
and the red ones to the centers where it was not rejected.
In both c(1) and c(2) the study was terminated after the first
stage (their p-values are less than α1). However, the decision
to reject the null for c(2) depends on the results in the centers
c(3) and c(4). On the left-hand side, the null is rejected at c(2)
and c(3). On the right-hand side, decisions about c(2), c(3), c(4)
are all non-rejections.
only occurs when we stop after the first stage, does not necessarily mean that
for this center the null is rejected. If the design parameter α1 is such that
α(1) > α1, the rejection always occurs. Otherwise, the rejection depends on
the other p-values or, more precisely, on their arrangement with regard to
α(k) which is only known at the completion of the second stage.
Consider two p-value realisations shown in Fig.5. There are two centers,
c(1), c(2) where the trial was stopped after the first stage, and their p-values
are less than α1. In two other centers the second stage was conducted and
their p-values are in the interval (α1, 1 − α0). For c(1) the null is rejected
after the first stage in both situations, because p-value1 < α(1), but the
decision about c(2) depends on the results in the centers where the second
stage is conducted. To summarize, if for some center after the first stage
α(k) < p-value(k) < α1, the final decision about this center might depend
on the results from the centers where the trial continues to the second stage.
Recall that the type II error is defined as ”at least m false nulls among
M1 centers with strong effect are not rejected, m ≤ M1 ≤ M”. Denote the
maximum type II error rates as βsefw(M1,m). It is complicated to calculate
βsefw(M1,m) exactly for arbitrary couples (M1, m), but the upper bound can
be obtained rather straightforwardly. To do this, we introduce auxiliary
values
βsej =
{
βse(n, α(j)), one-stage design,
βse2 (D,α(j)), two-stage design.
(7)
Lemma 4. The following inequality always holds:
(8) 1− βsefw(M1,m) ≥
(
1− βseM1+1−m
)M1+1−m .
If M1 = M and m = 1, equality is achieved.
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From this lemma, we conclude that βsefw(M1,m) ≤ 1−
(
1− βseM1+1−m
)M1+1−m
and βsefw(M, 1) = 1− (1− βseM )M .
3. Planning the trial
In this section we present a framework which helps the user to choose
the design parameters in order to control the type II error rate below some
given level βmax or the power above (1 − βmax). For the multi-centre trial
we suggest to control βsefw(M, 1). Here we assume βmax < 0.5 for the single
center RCT and βmax < 1−0.5M for the multicenter RCT. At the beginning
the user should carefully define the region of strong effect as in Definition
1. Next, the user chooses βmax and the design parameters. We also provide
additional information that may influence the user’s choice of βmax. In
the case of changing βmax, one should recalculate the design parameters.
To illustrate the planning procedure, we use the region of strong effect as
depicted in Fig. 6 and βmax = 0.2.
3.1. Planning a single center RCT.
3.1.1. One-stage design: choosing the sample size. The planning of a single
center trial proceeds by choosing α and computing the sample size that
ensures the desired minimal power. After α is chosen (here and elsewhere
α = 0.05), n is computed as
n = min (n : βse(n, α) ≤ βmax) .(9)
To compute βse(n, α), we use an asymptotic approximation of β(n, η, µ, p)
based on the central limit theorem. Notice that Y T1 , . . . , Y
T
n are i.i.d. random
variables with E
(
Y Ti
)
= µp and V ar
(
Y Ti
)
= 1 + (1− p)pµ2. Hence,
Y T ∼ N
(
µp,
1 + (1− p)pµ2
n
)
, X ∼ N
(
µp,
1 + (1− p)pµ2
n
+
1
n
)
.
With Barry–Essen’s upper bound ( [11, 10]) on the absolute deviation of the
probability of a false negative from its normal approximation, we have
(10)
∣∣∣∣∣β(n, η, µ, p)− Φ
( √
n(η − µp)√
2 + (1− p)pµ2
)∣∣∣∣∣ ≤ C√n.
We use this normal approximation in the following computations, because
the real difference in (10) is negligible even for small sample sizes. From
Lemma 2,
βse(n, α) ≈ max
i=1,...,s
Φ
√2z1−α −√nµipi√
2 + (1− pi)piµ2i

and
n ≈ max
i=1,...,s
√2z1−α + z1−βmax
√
2 + (1− pi)piµ2i
µipi
2 .(11)
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µ
p
E
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
0
0.2
0.4
0.6
0.8
1
Figure 6. Region of strong effect, characterised by ~µ =
(2, 1, 0.7), ~p = (0.2, 0.4, 0.6).
Example. Let the region E be as in Fig. 6 and let the maximum type II error
rate be 0.2. The minimum sample size for the trial with these parameters
from (11) is n ≈ 85.3, whereas the exact value from (9) is 86. For n = 86
and α = 0.05, the rejection threshold η = 0.251 and it is straightforward to
conduct the trial (D1).
3.1.2. Two-stage design. The design is determined by D = {n1, α0, α1, n2}.
After α is chosen, the sample size at the second stage is computed as
n2 = min (n : β
se
2 (D,α) ≤ βmax) .(12)
To approximate n2, we use the following approximation for the type two
error for the two-stage design:
β2(D,α, µ, p)
≈ Φ
( √
n1(η0 − µp)√
2 + (1− p)pµ2
)
+
∫ η1
η0
ϕ
( √
n1(x1−µp)√
2+(1−p)pµ2
)
√
2+(1−p)pµ2
n1
Φ
 n1+n2n2 η2(D,α)− n1n2x1 − µp√
2+(1−p)pµ2
n2
 dx1.
We next compute n2 numerically. Note that it is possible that no design
fulfills the condition on βmax. In the following we will address this problem.
For planning purposes we next consider the expected sample size under
the null,
(13) q0(D) = n1 + (1− α0 − α1)n2
and the analogous formula for the maximum expected sample size under the
alternative is
(14)
q1(D) = n1 + max
µ>0, p>0
(
β
(
n1,
√
2 z1−α1√
n1
, µ, p
)
− β
(
n1,
√
2 zα0√
n1
, µ, p
))
n2.
In this paper we put α0 > 0.5 in order to stop the trial early in the case of
the absence of the effect. With this choice, both z1−α1 and zα0 are positive.
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Figure 7. Possible pairs of (n1, α0) for the two-stage de-
sign. The parameters are α = 0.05, βmax = 0.2, n = 86;
12 ≤ n1 ≤ 86.
Lemma 5. If 0 < zα0 < z1−α1, the maximum probability of conducting the
second stage in (14) approximately satisfies
(15)
max
µ>0, p>0
(
β
(
n1,
√
2 z1−α1√
n1
, µ, p
)
− β
(
n1,
√
2 zα0√
n1
, µ, p
))
≈ 2Φ
(
z1−α1 − zα0
2
)
−1.
The maximum is achieved for µ =
z1−α1+zα0√
2n1
, p = 1.
From Lemma 5, it follows that q1(D) ≈ n1 +
(
2Φ
(
z1−α1−zα0
2
)
− 1
)
n2.
We let the user choose n1 and α0, but we suggest setting α1 such that it
minimizes q1(D) for given n1, α0. This leads to the choice α1 = argmin
α1
q1(D).
Once n1, α0, α1 have been fixed, all the other quantities including n2, q0, q1
can be computed.
In the following we discuss guidance for the user on the choice of n1 and α0.
We suppose that the choice of n1, α0 is based on q0, q1 and n2. We note that
the design does not exist for every pair (n1, α0). With 0.5 < α0 < 1−α and
(6), we have βse(n1, 1−α0) < βse2 (D,α) ≤ βmax, and with an approximation
for βse(n1, 1− α0), mentioned above,
(16) α0 < min
i=1,...,s
Φ
(√
n1
2
µipi − z1−βmax
√
1 +
(1− pi)pi
2
µ2i
)
.
This in turn implies that
n1 >
 max
i=1,...,s
z1−βmax
√
2 + (1− pi)piµ2i
µipi
2 .(17)
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(a) q0n . min q0 = 60 for n1 = 45, α0 = 0.75.
(b) q1n . min q1 = 75 for n1 = 55, α0 = 0.75
(c) n1+n2n
Figure 8. The diagnostic plot for choosing the design. The
parameters are α = 0.05, βmax = 0.2, ~µ = (2, 1, 0.7), ~p =
(0.2, 0.4, 0.6), n = 86. The color coding indicates the per-
centage gain in sample size compared to the one stage de-
sign. Small values below one indicate a gain, and values
above 1 indicate a loss. The green square in (a) is a pair of
parameters that attains the minimum of q0, whereas the red
square in (b) attains the minimum for q1. These points are
also shown in (c). For the choice n1 = 55, α0 = 0.7, α1 =
0.026, n2 = 38, η0 = 0.10, η1 = 0.37, η2 = 0.26, we have
q0 = 66, q1 = 75, n1 + n2 = 93.
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Figure 9. Probability of a false negative computed for
n1 = 55, α0 = 0.7, α1 = 0.026, n2 = 38.
The first stage sample size also should satisfy n1 < n, otherwise the two-
stage scheme is less efficient than the one-stage design. Based on (16) and
(17), the region of possible (n1, α0) provided to the user is shown in Fig.7.
Among all possible pairs (n1, α0) one would choose ones that make the
values of q0, q1 and n1+n2 small. However, these criteria cannot be achieved
simultaneously. This trade-off is left for the user to resolve, and in Fig.8 we
provide an example of a graphical help for the choices. Recall that the design
is built to ensure the type II error rate to be not greater than βmax in all the
corners of E . However, this probability can be very sensitive to µ and/or
p. We assume that given the probability of a false negative for all (µ, p),
as shown in Fig.9, the user may decide to change βmax. If these rates are
small, the trial size may be reduced by using a larger βmax, and if βmax is
considered to be reduced, then the larger trial is necessary. If he decides to
change βmax, the design needs to elaborated from the beginning.
3.2. Planning a multicenter RCT. The design is determined by the set
{M,n1, α0, α1, n2}. For the multicenter trial we build the design to control
βsefw(M, 1). The type II error rates β
se
fw(M1,m) where M1 < M or m > 1
are not controlled. From Lemma 4, the condition βsefw(M, 1) ≤ βmax is
equivalent to βseM ≤ 1 − (1 − βmax)
1
M . This means that if we consider M
centers separately, the design in each of the centers will correspond to the
single center RCT with the type I and type II errors controlled at levels
α(M), the largest threshold of the multiple rejection procedure, and βseM =
1− (1− βmax) 1M , respectively.
To illustrate the planning for the RCT with four centers, consider that
FWER is controlled at 0.05 and the family-wise type II error rate is con-
trolled at βmax = 0.2. With Hochberg’s multiple procedure the design is
then determined by α(4) = 0.05 and βseM = 1 − (1 − 0.2)
1
4 ≈ 0.054. As in
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(a) q0n . min q0 = 113 for n1 = 85, α0 = 0.7.
(b) q1n . min q1 = 134 for n1 = 105, α0 = 0.75
(c) n1+n2n
Figure 10. The diagnostic plot for choosing the design.
The parameters are M = 4, α = 0.05, βmax = 0.2, ~µ =
(2, 1, 0.7), ~p = (0.2, 0.4, 0.6), n = 153. For the parameters
n1 = 100, α0 = 0.7, α1 = 0.026, n2 = 65, η0 = 0.07, η1 =
0.28, η2 = 0.19, we have q0 = 118, q1 = 134, n1 + n2 = 165.
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the single center RCT, the choice of n1 and α0 is made by the user based
on the information provided in Fig.10.
Nonetheless, maximum type II error rates for M1 < M or m > 1 can be
also of interest for the study. Even if an effect exists, it is not necessarily
strong in all centers. Furthermore, a trial missing a few centers with strong
effect can still be useful if in the other centers it is detected. Hence, given the
information about βsefw(M1,m), the user might change βmax and recalculate
the design. In Lemma 4, we show an upper bound on these errors,
βsefw(M1,m) ≤ 1−
(
1− βseM1+1−m
)M1+1−m .
Once the parameters n1, α0 have been chosen, the user is supplied with
Table 1(a).
We do not know an exact value of βsefw(M1,m), but we can compute the
type II error rate βfw(M1,m) for the given responses (the details can be
found in Appendix B). the user has a better intuition about βsefw(M1,m) if
we provide him with βfw(M1,m) computed for different sets of responses. We
take M1 centres with the same (µ
∗, p∗) ∈ E , while in the remaining M −M1
centres H0 is true (see Table 1 (b),(c)). We suggest that the user checks
more than one pair (µ∗, p∗) to have a better understanding of possible type
II error rates. Based on these tables, the user decides whether to change
βmax or not.
As illustrated, the values of βfw(M1,m) are very sensitive to the true
parameters (µ∗, p∗). In Tab.1(b), we took µ∗ = 2, p∗ = 0.2, which is the
lowest corner of E , while in Tab.1(c), µ∗ = 1.2, p∗ = 0.5 is inside E but not
far away from the boundary.These numbers show that βfw(M1,m) decreases
rapidly when µ∗ and/or p∗ increases.
M1
1 2 3 4
m
1 0.305 0.469 0.534 0.200
2 0.305 0.469 0.534
3 0.305 0.469
4 0.305
(a) Upper bound on βsefw(M1,m).
M1
1 2 3 4
m
1 0.303 0.464 0.515 0.200
2 0.091 0.170 0.099
3 0.026 0.030
4 0.004
(b) βfw(M1,m) for (µ
∗, p∗) =
(2, 0.2).
M1
1 2 3 4
m
1 0.032 0.050 0.050 0.002
2 0.001 0.002 < 0.001
3 < 0.001 < 0.001
4 < 0.001
(c) βfw(M1,m) for (µ
∗, p∗) =
(1.2, 0.5).
Table 1. βfw(M1,m). The design parameters are α =
0.05, βmax = 0.2, n1 = 100, α0 = 0.7, α1 = 0.026, n2 = 65.
Real parameters in the centers with strong effect are (µ∗, p∗),
for the other centers H0 is true.
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4. Examples
To validate the model, we take the parameters from the previous section:
M = 4, α = 0.05, βmax = 0.2, n1 = 100, α0 = 0.7, α1 = 0.026, n2 = 65.
For different M1 and m we simulate the trial 1000 times. The responses in
the control and treatment groups are, ZC ∼ N (0, 1), ZT ∼ (1−p∗)N (0, 1)+
p∗N (µ∗, 1). We estimate the standard deviation as σˆ =
√∑n
i=1(Z
C
i −µˆC)2
n−1 .
The results are summarized in Tab.2.
M1
1 2 3 4
m
1
0.303 0.464 0.515 0.200
0.294 0.498 0.523 0.185
2
0.091 0.170 0.100
0.099 0.179 0.079
3
0.026 0.030
0.032 0.032
4
0.004
0.007
(a) For the centres with strong ef-
fect (µ∗, p∗) = (2, 0.2).
M1
1 2 3 4
m
1
0.032 0.050 0.050 0.002
0.041 0.044 0.043 0.005
2
0.001 0.002 < 0.001
0.001 0 0
3
< 0.001 < 0.001
0 0
4
< 0.001
0
(b) For the centres with strong ef-
fect (µ∗, p∗) = (1.2, 0.5).
Table 2. Theoretical (top) and empirical (bottom)
βfw(M1,m) for 1000 simulations. The parameters are M =
4, α = 0.05, βmax = 0.2, n1 = 100, α0 = 0.7, α1 =
0.026, n2 = 65.
5. Discussion
Region of strong effect. The region of strong effect for the mixture re-
sponse model was introduced as an instrument for decision making. Further
standardization for regulatory reasons might be of interest. From our point
of view, it may also assist in making the research on trial designs more co-
herent. In our framework we suggest to first determine the region of strong
effect. while βmax and other parameters may be tuned according to the
needs of the study.
Mean value statistic. The choice of the mean value statistic is not only
motivated by its simplicity and its role in the classical RCT design. The
mean value statistic also has some advantages for the mixture models. If
responses in the control and treatment groups, Y C and Y T , have densities
f(y) and (1− p)f(y) + pf(y − µ), respectively, and V ar (Y C) = 1, then by
the central limit theorem the following approximations hold
Y T ∼ N
(
µp,
1 + (1− p)pµ2
n
)
, X ∼ N
(
µp,
1 + (1− p)pµ2
n
+
1
n
)
.
This means that all the designs presented in the paper may be used for
non-normal responses.
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(a) Single center trial. The maxi-
mum probability is 0.52.
(b) Multicenter trial. The maximum
probability is 0.52.
Figure 11. The plot is in the (µ, p) space and shows the re-
gion of strong effect together with the probability of conduct-
ing the second stage. On the left is the case of a single center
RCT and on the right is the case of 4 centers RCT. In each
case the red dot, (0.24, 1) on the left and (0.17, 1) on the right,
shows the worst combination of µ and p in terms of the ex-
pected sample size under the alternative. The design on the
left is n1 = 55, α0 = 0.7, α1 = 0.026, n2 = 38, whereas on the
right it has M = 4, n1 = 100, α0 = 0.7, α1 = 0.026, n2 = 65.
In the two-stage design we use the criterion X > η2 to decide on rejection
of the null after the second stage. It is not obvious why this test works well
and why X1 and X2 are not combined in some other way, but the proposed
test is close to the UMP. The likelihood ratio based on the joint distribution
function of
(
X1, X2
)
is
(18)
g(X1,X2)(x1, x2)
f(X1,X2)(x1, x2)
=
ϕ
(√
n1
2
x1−µp√
1+
(1−p)p
2
µ2
)
ϕ
(√
n2
2
x2−µp√
1+
(1−p)p
2
µ2
)
ϕ
(√
n1
2 x1
)
ϕ
(√
n2
2 x2
)
≈ ϕ
(√
n1
2 (x1 − µp)
)
ϕ
(√
n2
2 (x2 − µp)
)
ϕ
(√
n1
2 x1
)
ϕ
(√
n2
2 x2
) = e (x1n1+x2n2)µp− 12 (µp)22 ,
where f(x1, x2) and g(x1, x2) are pdfs under the null and alternative, re-
spectively. The normal approximation in the likelihood works if the variance
1 + (1−p)pµ
2
2 is close to one. In this case likelihood ratio is the monotone
non-decreasing function of x1n1+x2n2n1+n2 . The test becomes UMP when p = 1.
Expected sample size. As we have seen in Sec.3, the minimum value of
the optimized q1 is quite close to n. This value is reached for the ’worst’
alternative µ =
z1−α1+zα0√
2n1
, p = 1 and for other values it can be substantially
lower. And in many situations we have much smaller expected sample size.
To illustrate this, we plot the probability to conduct the second stage for
the chosen in Sec.3 single- and multicenter designs (see Fig.11). This graph
might be also of interest for the user during the design planning.
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Rejection procedures for multicenter trials. For multicenter RCTs,
we construct the design using Hochberg’s step-up rejection procedure. How-
ever, one can use any step-up procedure with thresholds α(1), ..., α(M). For
example, it could be Benjamini-Hochberg’s procedure ( [9]) with α(k) = kαM
which controls the false discovery rate (FDR). There will be no difference in
parameters {n1, α0, α1, n2} for the designs using Hochberg’s or Benjamini-
Hochberg’s procedures to control βsefw(M, 1), because in each center the de-
sign corresponds to the single center RCT with the maximum type I er-
ror rate controlled at the same level α(M) = α (see (7) and Lemma 4).
If M = 2, these methods are fully equivalent, including the thresholds
α(1) = α/2, α(2) = α. Nonetheless, if M > 2, βsefw(M1,m) is generally
smaller for the Benjamini-Hochberg procedure (see Tab.3).
M1
1 2 3 4
m
1
0.303 0.464 0.515 0.200
0.298 0.380 0.200 0.200
2
0.091 0.170 0.099
0.082 0.069 0.027
3
0.026 0.030
0.014 0.009
4
0.004
0.002
(a) For the centres with strong ef-
fect (µ∗, p∗) = (2, 0.2).
M1
1 2 3 4
m
1
0.032 0.050 0.050 0.002
0.032 0.033 0.003 0.002
2
0.001 0.002 < 0.001
< 0.001 < 0.001 < 0.001
3
< 0.001 < 0.001
< 0.001 < 0.001
4
< 0.001
< 0.001
(b) For the centres with strong ef-
fect (µ∗, p∗) = (1.2, 0.5).
Table 3. βfw(M1,m) for Hochberg’s (top) and Benjamini-
Hochberg’s (bottom) rejection rules. The parameters are
M = 4, α = 0.05, βmax = 0.2, n1 = 100, α0 = 0.7, α1 =
0.026, n2 = 65.
To emphasize the importance of step-up procedures, consider the classical
Bonferroni correction. For this procedure the decision is made for each
center individually. However, the method may be reformulated as a step-up
procedure with α(k) = αM for k = 1, ...,M . An additional constraint for
the two-stage design will be α1 <
α
M . If this is not satisfied, the second
stage is not needed. In Fig.12, we give a diagnostic plot similar to those
in Fig.10 for the Bonferroni method. First, the sample size for the one-
stage design is n = 209, while for Hochberg’s and Benjamini-Hochberg’s
procedures n = 153 < 209.
The minimum values of q0, q1, n1 + n2 for the Bonferroni method are
also considerably higher than for the step-up procedures (q0 = 118, q1 =
134, n1 + n2 = 165). Therefore, the designs using Hochberg’s step-up pro-
cedure controls the same FWER as the Bonferroni and is clearly superior in
terms of effort.
Random treatment effect. In our model the treatment-specific effect for
the drug responders is a fixed value µT − µC . However, a more realistic
model might consider it to be random. To address this issue, we present
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(a) q0n .
min q0 = 134 for n1 = 100, α0 = 0.775.
(b) q1n .
min q1 = 185 for n1 = 140, α0 = 0.875.
(c) n1+n2n .
min(n1 + n2) = 209 for n1 = 205, α0 = 0.55.
Figure 12. The diagnostic plot for choosing the design.
The parameters are M = 4, α = 0.05, βmax = 0.2, ~µ =
(2, 1, 0.7), ~p = (0.2, 0.4, 0.6). For the Bonferroni procedure
n = 209.
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type II error rates for the chosen designs if the treatment-specific effect is
random variable from N (µT − µC , δ2). There, ZT ∼ (1 − p)N (µC , σ2) +
pN (µT , σ2+δ2). In Tab.4, average empirical type II error rates for the fixed
and random treatment-specific effects are given. We observe bigger error
rates when an effect is random. This might be taken into account for the
development of the design.
M1
1 2 3 4
m
1
0.294 0.498 0.523 0.185
0.321 0.519 0.571 0.355
2
0.099 0.179 0.079
0.111 0.22 0.193
3
0.032 0.032
0.038 0.068
4
0.007
0.009
(a) For the centres with strong ef-
fect (µ∗, p∗) = (2, 0.2).
M1
1 2 3 4
m
1
0.041 0.044 0.043 0.005
0.150 0.279 0.353 0.253
2
0 0 0
0.038 0.075 0.072
3
0 0
0.008 0.012
4
0
0
(b) For the centres with strong ef-
fect (µ∗, p∗) = (1.2, 0.5).
Table 4. Empirical type II error rates based on 1000
simulations. ZC ∼ N (0, 1), ZT ∼ (1 − p∗)N (0, 1) +
p∗N (µ∗, 1) for fixed effect (top) and ZT ∼ (1− p∗)N (0, 1) +
p∗N (µ∗, 1 + 0.52) for random effect (bottom) effects. The
parameters are M = 4, α = 0.05, βmax = 0.2, n1 =
100, α0 = 0.7, α1 = 0.026, n2 = 65.
Estimation of µT , µC , σ and p. For the classical sequential RCT design
(no mixture response) the estimation of the parameters is discussed in [16,
17, 18], and [19]. In the mixture framework, to characterize the sensitive
subgroup, one would like to have estimators of µT , µC , σ and p. We do not
further investigate this question, but there are some estimation procedures
that can be applied to the data. A large literature covers various aspects
of estimation of the mixture model parameters. In the case of a one-stage
design, one can use the likelihood-based estimators of µT , µC , σ and p (e.g.,
the EM algorithm or the method proposed in [20]). Regarding a two-stage
trial, one can apply these algorithms to either the first or the second stage
results.
6. Conclusion
In this paper we extend the classical continuous response RCT design to
the case when a fraction of the treated patients responds to the tested treat-
ment. The response in the treatment group is modelled as a two-component
mixture, representing placebo and drug responders.
We modified the conventional procedure that decides on the existence of
a treatment-specific effect to a test that decides on the existence of a drug-
responders subgroup. We characterize the latter by the fraction p > 0 and
the treatment-specific effect µ > 0. We assume that pairs (µ, p) of potential
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interest belong to the set E , the region of strong effect. The trial protocol
is then determined by the testing procedure that ensures a certain power of
detection for any subgroup whose parameter is in E . We developed one- and
two-stage RCT designs along with the exact and approximate expressions for
the type II error rates. We also generalized these designs to the multicenter
framework where we control the family-wise error rate. To decrease the
sample size, we use Hochberg’s step-up multiple test. If one wants to control
FDR, one may simply use Benjamini–Hochberg’s test or any other suitable
thresholds. We provide the graphical help to guide the user in choosing
design parameters, where a few are determined by minimizing the required
effort.
Appendix A. Mathematical proofs
Lemma 1. The tests that reject H0 for X > η are uniformly most powerful.
Proof. We denote the pdf of X under H0 as f(x) and the pdf of X under an
alternative as g(x). The function g(x)f(x) is non-decreasing in x if µ > 0, since
g(x)
f(x)
=
n∑
k=0
(
n
k
)
pk(1− p)n−k f
(
x− knµ
)
f(x)
=
n∑
k=0
(
n
k
)
pk(1− p)n−ke
n
2
(
x k
n
µ− 1
2(
k
n
µ)
2
)
.
From the Karlin–Rubin theorem it follows that the test X > η is UMP. 
Lemma 2. For a region of strong effect as defined in Fig.2, the maximum
type II error rate in the region of the strong effect satisfies
(19) βse(n, α) = max
i=1,...,s
β(n, z1−α
√
2
n
, µi, pi)
Proof. The probability of a false negative is
β(n, η, µ, p) =
n∑
k=0
(
n
k
)
pk(1− p)n−kΦ
(√
n
2
(
η − k
n
µ
))
.
The maximum value is attained in one of the corners of E . Indeed, this
follows from
∂β
∂µ
(n, η, µ, p) < 0 and
∂β
∂p
(n, η, µ, p) < 0.
(20)
∂β
∂µ
(n, η, µ, p) = −
n∑
k=0
(
n
k
)
pk(1− p)n−k k√
2n
ϕ
(√
n
2
(
η − k
n
µ
))
< 0;
(21)
∂β
∂p
(n, η, µ, p) = n
n∑
k=1
(
n− 1
k − 1
)
pk−1(1− p)n−kΦ
(√
n
2
(
η − k
n
µ
))
− n
n−1∑
k=0
(
n− 1
k
)
pk(1− p)n−k−1Φ
(√
n
2
(
η − k
n
µ
))
= n
n−1∑
k=0
(
n− 1
k
)
pk(1− p)n−k−1
(
Φ
(√
n
2
(
η − k + 1
n
µ
))
− Φ
(√
n
2
(
η − k
n
µ
)))
< 0.
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
Lemma 3. For the region of strong effect defined as in Definition 1, the
maximum type II error rate for the two-stage trial is
βse2 (D,α) = max
i=1,...,s
β2(D,α, µi, pi).
Proof. This can be shown by proving that
∂β2
∂µ
(n1, η0, η1, n2, α, µ, p) < 0 and
∂β2
∂p
(n1, η0, η1, n2, α, µ, p) < 0.
We will use inequalities ∂β∂µ(n, η, µ, p) < 0 and
∂β
∂p (n, η, µ, p) < 0 from Lemma 2
and inequality ∂β∂η (n, η, µ, p) > 0, which is a trivial consequence from (3).
There are two different cases:
1. α /∈ (α1, 1− α0):
∂β2
∂µ
(n1, η0, η1, n2, α, µ, p) =
∂β
∂µ
(n1, z1−α
√
2
n1
, µ, p) < 0,
∂β2
∂p
(n1, η0, η1, n2, α, µ, p) =
∂β
∂p
(n1, z1−α
√
2
n1
, µ, p) < 0.
2. α ∈ (α1, 1− α0):
∂β2
∂µ
(n1, η0, η1, n2, α, µ, p) =
∂β
∂µ
(n1, η0, µ, p) +
∫ η1
η0
∂β
∂η∂µ
(n1, x1, µ, p)β (n2, x2(x1), µ, p) dx1
+
∫ η1
η0
∂β
∂η
(n1, x1, µ, p)
∂β
∂µ
(n2, x2(x1), µ, p) dx1 =
∂β
∂µ
(n1, η0, µ, p)
+
∂β
∂µ
(n1, x1, µ, p)β (n2, x2(x1), µ, p)
∣∣∣∣η1
η0
+
n1
n2
∫ η1
η0
∂β
∂µ
(n1, x1, µ, p)
∂β
∂η
(n2, x2(x1), µ, p) dx1
+
∫ η1
η0
∂β
∂η
(n1, x1, µ, p)
∂β
∂µ
(n2, x2(x1), µ, p) dx1 =
∂β
∂µ
(n1, η0, µ, p) (1− β (n2, x2(η0), µ, p))
+
∂β
∂µ
(n1, η1, µ, p)β (n2, x2(η1), µ, p) +
n1
n2
∫ η1
η0
∂β
∂µ
(n1, x1, µ, p)
∂β
∂η
(n2, x2(x1), µ, p) dx1
+
∫ η1
η0
∂β
∂η
(n1, x1, µ, p)
∂β
∂µ
(n2, x2(x1), µ, p) dx1 < 0;
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∂β2
∂p
(n1, η0, η1, n2, α, µ, p) =
∂β
∂p
(n1, η0, µ, p) +
∫ η1
η0
∂β
∂p∂η
(n1, x1, µ, p)β (n2, x2(x1), µ, p) dx1
+
∫ η1
η0
∂β
∂η
(n1, x1, µ, p)
∂β
∂p
(n2, x2(x1), µ, p) dx1 =
∂β
∂p
(n1, η0, µ, p)
+
∂β
∂p
(n1, x1, µ, p)β (n2, x2(x1), µ, p)
∣∣∣∣η1
η0
+
n1
n2
∫ η1
η0
∂β
∂p
(n1, x1, µ, p)
∂β
∂η
(n2, x2(x1), µ, p) dx1
+
∫ η1
η0
∂β
∂η
(n1, x1, µ, p)
∂β
∂p
(n2, x2(x1), µ, p) dx1 =
∂β
∂p
(n1, η0, µ, p) (1− β (n2, x2(η0), µ, p))
+
∂β
∂p
(n1, η1, µ, p)β (n2, x2(η1), µ, p) +
n1
n2
∫ η1
η0
∂β
∂p
(n1, x1, µ, p)
∂β
∂η
(n2, x2(x1), µ, p) dx1
+
∫ η1
η0
∂β
∂η
(n1, x1, µ, p)
∂β
∂p
(n2, x2(x1), µ, p) dx1 < 0,
where x2(x1) =
n1+n2
n2
η2(n1, η0, η1, n2, α)− n1n2x1. 
Lemma 4. The following inequality always holds:
(22) 1− βsefw(M1,m) ≥
(
1− βseM1+1−m
)M1+1−m .
If M1 = M and m = 1, equality is achieved.
Proof. Consider an arbitrary set of p-values: p-value1, . . . , p-valueM of
whichM1 correspond to the alternatives with the strong effect. Let βfw(M1,m)
be the type II error rate for these p-values. We will show that
1− βfw(M1,m) ≥
(
1− βseM1+1−m
)M1+1−m .
Then, for the set of p-values where the maximum type II error rate is
achieved, the statement in the lemma holds. Let S1 be the set of indexes for
the centres with the strong effect. Define k˜ as the rank of the m-th highest
p-value among S1,
(23)
∑
c(k)∈S1
1(k ≥ k˜) = m.
First, we will prove that
(24) 1− βfw(M1,m) ≥ P
(
p-value(k˜) ≤ α (M1 + 1−m)
)
.
By definition, k˜ ≥M1 + 1−m. The condition p-value(k˜) ≤ α (M1 + 1−m)
is sufficient to reject at least M1+1−m null hypotheses for the centers with
strong effect and therefore to avoid type II error. The second inequality we
have to prove is
(25) P
(
p-value(k˜) ≤ α (M1 + 1−m)
)
≥ (1− βseM1+1−m)M1+1−m .
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For the proof we will use S2, an arbitrary subset of centers with strong
effects such that |S2| = M1 + 1−m:
(26)
P
(
p-value(k˜) ≤ α (M1 + 1−m)
)
= P
∑
ck∈S1
1 (p-value(k) ≤ α (M1 + 1−m)) ≥M1 + 1−m

≥ P
∑
i∈S2
1 (p-valuei ≤ α (M1 + 1−m)) ≥M1 + 1−m

≥ (1− βseM1+1−m)M1+1−m .
If M1 = M and m = 1 then the inequality (24) becomes an equality, because
in this case k˜ = M and condition p-value(M) ≤ α(M) is necessary and
sufficient to reject all null hypotheses. Also if P (p-valuei ≤ α(M)) = 1−βseM
for all i then the inequality (25) becomes an equality:
(27)
P (p-value(M) ≤ α(M)) = P (p-valuei ≤ α(M), ∀i = 1, . . . ,M) = (1− βseM )M .

Comment : If M1 < M or m > 1, equality in (24) cannot be attained,
because there is a non-zero probability of having
k˜ = M1+1−m, p-value(k˜), p-value(k˜+1) ∈ (α(M1 + 1−m), α(M1 + 2−m)] ,
in this case there is no type II error.
From this lemma, we conclude that
βsefw(M1,m) ≤ 1−
(
1− βseM1+1−m
)M1+1−m ,
and
βsefw(M, 1) = 1− (1− βseM )M .
Lemma 5. If 0 < zα0 < z1−α1, the maximum probability of conducting the
second stage in (14) approximately satisfies
(28)
max
µ>0, p>0
(
β
(
n1,
√
2 z1−α1√
n1
, µ, p
)
− β
(
n1,
√
2 zα0√
n1
, µ, p
))
≈ 2Φ
(
z1−α1 − zα0
2
)
−1.
The maximum is achieved for µ =
z1−α1+zα0√
2n1
, p = 1.
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Figure 13. βi,j for the multiple testing procedure.
Proof. To show this, we bound the probability of conduction the second
stage as follows:
max
µ>0, p>0
(
β
(
n1,
√
2 z1−α1√
n1
, µ, p
)
− β
(
n1,
√
2 zα0√
n1
, µ, p
))
≈ Φ
(√
2z1−α1 −
√
n1µp√
2 + (1− p)pµ2
)
− Φ
( √
2zα0 −
√
n1µp√
2 + (1− p)pµ2
)
≤ Φ
(√
2z1−α1 − (
√
2z1−α1 +
√
2zα0)/2√
2 + (1− p)pµ2
)
− Φ
(√
2zα0 − (
√
2z1−α1 +
√
2zα0)/2√
2 + (1− p)pµ2
)
= 2Φ
(√
2z1−α1 −
√
2zα0√
2 + (1− p)pµ2
)
− 1 ≤ 2Φ
(
z1−α1 − zα0
2
)
− 1.
Notice, that an equality is achieved for µ =
z1−α1+zα0√
2n1
> 0 and p = 1. This
ends the proof. 
Appendix B. Type II error rate for the multi-center design
computation
We do not know an exact value of βsefw(M1,m), but we can compute the
type II error rate βfw(M1,m) for the given responses. Let α(1) < α(2) <
· · · < α(M) be the p-value thresholds for the rejection procedure. For
convenience put α(0) = 0, α(M + 1) = 1. To compute βfw(M1,m), one
should look at the disposition of the p-values inside the intervals (α(j −
1), α(j)], j = 1, 2, . . . ,M + 1.
Define βi,j = P(p-valuei ≥ α(j)) to be the type II error for the i−th center
evaluated at α = α(j) (see Fig. 13). The probability that the p-value of the
i−th center is in the interval (α(j − 1), α(j)] is
(29)
P(p-valuei ∈ (α(j−1), α(j)]) = βi,j−1−βi,j , i = 1, . . . ,M ; j = 1, . . . ,M+1.
Notice that if p-values for some centres are in the same interval (α(j), α(j−
1)], the decision about H0 there will be the same.
Let the random index ji define an interval of the i−th center p-value,
(30) ji = (j | p-valuei ∈ (α(j − 1), α(j)]) , ji = 1, . . . ,M + 1.
ADAPTIVE DESIGNS IN THE PRESENCE OF UNKNOWN SENSITIVE SUBGROUP27
The probability of observing {j1, . . . , jM} is then expressed as
(31)
M∏
i=1
(βi, ji−1 − βi, ji) , where 1 = βi,0 > βi,1 > . . . > βi,M > βi,M+1 = 0.
Define ej to be the number of p-values falling in the interval (0, α(j)],
(32) ej = ej(j1, . . . , jM ) =
M∑
i=1
1 (ji ≤ j) .
Using ej , an alternative formulation of Hochberg’s step-up procedure is as
follows:
• Compute ej for each j = 1, . . . ,M ;
• Find the maximum J such that eJ ≥ J ;
• Reject H0 in centres ck, k = 1, . . . , eJ .
Let S1 be the set of indexes for the centers with the strong effects. Define
(33) j˜ = min
j |∑
i∈S1
1 (ji > j) < m

Now an expression for βfw(M1,m) can be written as
(34) βfw(M1,m) = P(ej < j, for all j ≥ j˜).
Consequently, one can compute the type II error rate as
(35) βfw(M1,m) =
M+1∑
j1=1
. . .
M+1∑
jM=1

ej<j for all j≥j˜
M∏
i=1
(βi,ji−1 − βi,ji) ,
which is the sum of the probabilities of all realisations {j1, . . . , jM}, such
that ej < j for all j ≥ j˜.
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